日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial

维多氟地莫司钙治疗复发型多发性硬化症的安全性和剂量反应:一项安慰剂对照 II 期试验的扩展结果

Fox, Robert J; Wiendl, Heinz; Wolf, Christian; De Stefano, Nicola; Sellner, Johann; Gryb, Viktoriia; Rejdak, Konrad; Bozhinov, Plamen S; Vitt, Daniel; Kohlhof, Hella; Slizgi, Jason; Ondrus, Matej; Sciacca, Valentina; Muehler, Andreas R

Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases

肠道屏障功能障碍在常见胃肠道疾病中的临床意义

Muehler, Andreas; Slizgi, Jason R; Kohlhof, Hella; Groeppel, Manfred; Peelen, Evelyn; Vitt, Daniel

Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease

胆汁酸作为评估多囊肾病肝功能损害的潜在生物标志物

Brock, William J; Beaudoin, James J; Slizgi, Jason R; Su, Mingming; Jia, Wei; Roth, Sharin E; Brouwer, Kim L R

Effect of Liver Disease on Hepatic Transporter Expression and Function.

肝脏疾病对肝脏转运蛋白表达和功能的影响

Thakkar Nilay, Slizgi Jason R, Brouwer Kim L R

Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes

夹层培养的人肝细胞中的肝细胞分布和转运蛋白与托伐普坦及其代谢物的相互作用

Yang Lu, Jason R Slizgi, Kenneth R Brouwer, Robert L St Claire, Kimberly M Freeman, Maxwell Pan, William J Brock, Kim L Brouwer

Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

托伐普坦及其代谢物对人类肝脏胆汁酸转运蛋白的抑制:导致药物性肝损伤的因素?

Jason R Slizgi, Yang Lu, Kenneth R Brouwer, Robert L St Claire, Kimberly M Freeman, Maxwell Pan, William J Brock, Kim L R Brouwer